Background: Anagen effluvium is a common side effect of chemotherapy, but few studies have examined its clinical characteristics. Objective: This study was aimed at evaluating the hair loss caused by chemotherapeutic agents. Methods: Sixty-four patients with anagen effluvium were evaluated in the study. Chemotherapeutic agents were classified into 5 different groups. The pattern of hair loss was analyzed when specific involvement of the hairline was obvious. Results: Forty-six (71.9%) of the 64 total patients maintained hairs along their hairline. Hairs were maintained with a total hairline in 20 (31.3%), frontal hairline in 13 (20.3%) and occipital hairline in 12 (18.8%) patients. Among the 20 males with patterned hair loss, the following hairlines were preserved: occipital in 10 (50%), total in 7 (35%) and frontal in 3 (15%). Among the 25 females with patterned hair loss, hairlines were preserved as total in 13 (52%), frontal in 10 (40%) and occipital in 2 (8%). However, no significant differences were detected in hair loss patterns according to age, associated symptoms, chemotherapeutic agent group or combination of chemotherapeutic agents. Conclusion: Our results suggest that anagen effluvium induced by chemotherapeutic agents represents patterned hair loss.

Keywords:
Anagen effluvium, Chemotherapeutic agents, Patterned hair loss
1.
Batchelor D: Hair and cancer chemotherapy: consequences and nursing care – A literature study. Eur J Cancer Care 2001;10:147–163.
2.
Williamson PJ, de Berker D: Pohl-Pinkus constrictions of hair following chemotherapy for Hodgkin’s disease. Br J Haematol 2005;128:582.
3.
Koppel RA, Boh EE: Cutaneous reactions to chemotherapeutic agents. Am J Med Sci 2001;321:327–335.
4.
Espinosa EE, Zamora P, Feliu J, Baron MG: Classification of anticancer drugs – A new system based on therapeutic targets. Cancer Treat Rev 2003;29:515–523.
5.
Hussein AM: Chemotherapy-induced alopecia: new developments. Southern Med J 1993;86:489–496.
6.
Kiebert GM, Hanneke J, De Haes CJM, Kievit J, Van de Velde CJH: Effect of peri-operative chemotherapy on the quality of life of patients with early breast cancer. Eur J Cancer 1990;26A:1038–1042.
7.
Paus R, Cotsarelis G: The biology of hair follicles. N Engl J Med 1999;341:491–497.
8.
Dunagin WG: Dermatological toxicity; in Perry MC, Yarbro JW (eds): Toxicity of chemotherapy. New York, Grune & Stratton, 1984, pp 125–145.
9.
Botchkarev VA: Molecular mechanisms of chemotherapy-induced hair loss. JID Symp Proc 2003;8:72–75.
10.
Sharov AA, Li GZ, Palkina TN, Sharova TY, Gilchrest BA, Botchkarev VA: Fas and c-kit are involved in the control of hair follicle melanocyte apoptosis and migration in chemotherapy-induced hair loss. J Invest Dermatol 2003;120:27–35.
11.
Howser DM: Alopecia – The problem of alopecia in cancer; in Groenwald SL, Frogge MH, Goodman M, et al (eds): Cancer Symptom Management. Boston, Jones & Bartlett, 1996, pp 261–268.
12.
Olsen EA: Female pattern hair loss. J Am Acad Dermatol 2001;45(suppl):S70–80.
13.
Norwood OT: Male pattern baldness: classification and incidence. South Med J 1975;68:1359–1365.
14.
Hamilton JB: Patterned loss of hair in men: types and incidence. Ann NY Acad Sci 1951;53:708–723.
15.
Ludwig E: Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. Br J Dermatol 1977;97:247–254.
16.
Sinclair R: Diffuse hair loss. Int J Dermatol 1999;38:8–18.
17.
Sawaya ME, Price VH: Different levels of 5α-reductase type I and II, aromatase, and androgen receptor in hair follicles of women and men with androgenetic alopecia. J Invest Dermatol 1997;144:297–304.
18.
Madani S, Shapiro J: Alopecia areata update. J Am Acad Dermatol 2000;42:549–566.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.